http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106916100-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1641 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2059 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate | 2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106916100-B |
| titleOfInvention | E-configuration benzamide compound and medicinal preparation thereof |
| abstract | The invention discloses an E-configuration benzamide compound, a medicinal preparation and an application thereof, wherein the E-configuration benzamide compound has a structure shown in a formula (I), and the chemical name of the E-configuration benzamide compound is N- (2-amino-4-fluorophenyl) -4- [ N- [ (E) -3- (3-pyridine) acryloyl group]Aminomethyl group]Benzamide, in the structural formula, the configuration of 3-pyridinylacryloyl is E type. The E-configuration benzamide compound shown in the formula (I) has subtype selective histone deacetylase inhibition activity, and mainly inhibits HDAC1, HDAC2, HDAC3 in class I HDAC and HDAC10 in class IIb HDAC. The E-configuration benzamide compound shown in the formula (I) can be used for treating diseases related to abnormal activity of histone deacetylase, such as cancers, including lymphoma, solid tumors, hematological tumors and the like. |
| priorityDate | 2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.